Efient er i kombination med acetylsalicylsyre (ASA) indiceret til forebyggelse af aterotrombotiske hændelser hos patienter med akut koronarsyndrom (dvs. ustabil angina, myokardieinfarkt uden elevation af ST- segment [UA/ NSTEMI] eller myokardieinfarkt [STEMI] med ST- segment elevation, som gennemgår primær eller forsinket perkutan koronarintervention (PCI).
Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i. e. unstable angina, non-ST segment elevation myocardial infarction [UA/ NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).